Search

EHA-SWG Scientific Meeting on Integrated Cell Tracking in Oncohematology: Diagnosis, Targeted Therapy and Residual Disease

Dates: November 10-12, 2022
Location: Bordeaux, France
Format: Hybrid
Chair: MC Béné

Registration has closed

This was the third time EHA is collaborating with the EHA Specialized Working Group on Diagnosis in hematological diseases, to bring you the latest in laboratory hematology.…

Read more

Collaboration with the EMA on Joint Clinical Assessments and Joint Scientific Consultations under the HTA Regulation

The European Hematology Association (EHA) welcomes the draft Implementing Act laying down procedural rules for the exchange of information between the Health Technology Assessment (HTA) Coordination Group, the European Commission, and the European Medicines Agency (EMA).

Read more

SWG Educational Activities

General meetings in 2023Meetings to discuss the progress and management of collaborations within the European networks.

Read more

EHA-SWG Scientific Meeting on Integrated Diagnosis Strategies in Oncohematology for the Management of Cytopenias and Leukocytosis

Dates: February 8-10, 2018 
Location: Barcelona, Spain
Chair: MC Béné
Co-chair: G Zini

Organized by: EHA & the EHA Scientific Working Group on Diagnosis: Morphology and Flow Cytometry

After a successful first edition in 2015, this meeting returns to Barcelona on February 8-10, 2018.…

Read more

EHA Endorsement of ESMO Clinical Practice Guidelines for Diagnosis, Treatment, and Follow-up of Chronic Lymphocytic Leukemia

European Hematology Association (EHA) and European Society for Medical Oncology (ESMO) agreed to collaborate on the production of European Guidelines for different hematological malignancies.

Read more

Proposal for an EU Regulation on Clinical Trials: A joint statement from non-commercial and commercial organisations

This statement outlines the areas of agreement within the health and research communities on where the Regulation will improve the research environment. Aspects of the Regulation that could be improved to further support clinical research are also highlighted.

Read more

EHA-SWG Scientific Meeting on Recent Advances in the Pathogenesis and Treatment of Secondary Acute Myeloid Leukemias

Dates: April 25-26, 2025
Location: Berlin, Germany
Chairs: K Döhner, P Vyas, and MT Voso
Collaborating SWG: EHA Specialized Working Group on Acute Myeloid Leukemia

Registration is now open

Program The EHA-SWG scientific meeting on Recent Advances in the Pathogenesis and Treatment of Secondary Acute Myeloid Leukemias will provide…

Read more

Novel basis for chemoresistance in AML: DNMT3A R882 mutations promote chemoresistance and residual disease through impaired DNA damage sensing

Although most acute myeloid leukemia (AML) patients initially respond to chemotherapy, the majority subsequently relapses and succumbs to refractory disease. Residual leukemic cells that survived chemotherapy may persist over time and later cause the disease to come back.

Read more

ABT-199: Novel Bcl-2 specific inhibitor updated results confirm substantial activity and durable responses in high-risk CLL.

Chronic Lymphocytic Leukaemia (CLL) is the most common leukemia in adults in the Western world and is diagnosed in approximately 5 persons per 100,000 population per year.

Read more